Tag Archives: Randy Vogenberg

Thoughts Around COVID-19: Linking Business & Healthcare

HR leaders need to coordinate on their P&Ps, best practices while collaborating with other executives around managing all risks. Vendors and healthcare supply chains serving the workplace need more collaboration as part of managing all risks related to this pandemic event.

Key Trends in Healthcare for 2020 and Beyond

Transparency has been elevated as consumerism marches forward in the face of steadily increasing healthcare costs

Insights Into Managing Health Benefits In This Era of Change

The healthcare marketplace is undergoing fast-paced changes fueled by political and regulatory events, medical, pharmaceutical and technology advancements, consumerism, and growing payer engagement in value-based reimbursement and contracting.

PBM P&T Practices The HEAT Initiative Is Gaining Momentum

Care outside the hospital, like P&T committee responsibilities outside the hospital, is necessarily different. New processes and solutions, such as cloud computing, can help improve performance and transparency of benefit management for purchasers or users of health care services. The current role of PBMs includes concurrent improvement in health outcomes, so the take-home message is […]

Employer Perspectives Specialty Drug Step-Therapy Program Evaluation

Employer Perspectives Specialty Drug Step-Therapy Program Evaluation American Health and Drug Benefits, September 2016 Vol 9, No 6 – Industry Trends Matthew Harman, PharmD, MPH, Director, Clinical Pharmacy Strategies Employers Health, Columbus, OH F. Randy Vogenberg, PhD, RPh, Strategic Advisor and Co–Project Leader, Midwest Business Group on Health National Employer Biologics & Specialty Drug Initiative […]

Current PBM Model Threatened by New-Entity PBMs

Changes are happening in the PBM market. Traditional services offered by PBMs will be supplanted by new PBM entities that will develop formularies among the services they offer. The new entity PBMs manage and supplement PBM services as an advocate for health care payers. Services include prescription claims analysis and consultation, drug coverage management, PBM contracts […]

Biosimilar Confusion and Insights

Since Virginia became the first state in May 2013 to enact legislation regulating a pharmacist’s substitution of an interchangeable biologic drug for a prescribed reference biologic drug, there has not been much activity or clarity on the issue. This issue continues to pit manufacturer versus manufacturer, and other stakeholders against each other in the policy […]

The Changing Roles of P&T Committees: A Look Back at the Last Decade and a Look Forward to 2020

Originally published at Pharmacy & Therapeutics – November 2014   http://www.nxtbook.com/nxtbooks/medimedia/pt_201411/src/forms/PT_November_2014_iframe_live.html#/38 Market and regulatory changes in the last 10 years, as well as the Affordable Care Act, have resulted in significant modifications to health care delivery models.  Traditionally, P&T committees limited the impact of their decisions to the populations associated with their hospital or health plan; […]